Company Overview of Merck Canada Inc.
Merck Canada Inc. researches, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and consumer care and animal health products. The company offers various vaccines for the prevention of rare diseases, such as measles and mumps, shingles, and cervical cancer; prescription products in various therapeutic areas, such as cardiovascular disease, respiratory disease, oncology, neuroscience, infectious disease, and women's health; and consumer healthcare products that help to prevent or treat various common conditions, including allergies, sun care, foot care, nasal and cough/cold care, digestive care, and more. It also offers veterinary medicines, including va...
16750 Trans Canada Highway
Kirkland, QC H9H 4M7
Founded in 1982
Key Executives for Merck Canada Inc.
President and Managing Director
President of Merck Research Laboratories
Vice President of Human Resources
Compensation as of Fiscal Year 2014.
Merck Canada Inc. Key Developments
Merck Canada Inc Appoints Chirfi Guindo to President and Managing Director
Oct 13 14
Merck Canada Inc. announced the appointment of Chirfi Guindo to President and Managing Director.
Merck Canada Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-17-2014 03:45 PM
Jun 17 14
Merck Canada Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-17-2014 03:45 PM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada. Speakers: Stephen Xanthoudakis.
CogState Limited Signs an Amendment to its Contract with Merck Canada Inc
Jun 2 14
CogState Limited has announced it has signed an amendment to its contract with Merck Canada Inc. allowing CogState to assume the full rights of promotion of COGNIGRAM in Canada, including direct liaison with physicians. Under the revised agreement, until March 1st, 2015, Merck Canada will continue to provide support with respect to e-marketing and reimbursement efforts for COGNIGRAM in Canada. CogState will retain 100% of revenue of any test sold and also take on all costs associated with the marketing and sales of the product. These new business to business opportunities include partnering with allied health care professionals already offering services in medical clinics; delivering COGNIGRAM testing directly onsite; licensing COGNIGRAM to hospitals and other institutions; offering COGNIGRAM to professional "brain worker" associations; and introducing COGNIGRAM to the wellness industry.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|